Gross expenditure on R&D (GERD) in South Africa rose 7.5% in fiscal 2013 to ZAR 23.9 billion ($2.2 billion). At 0.76%, GERD as a percentage of GDP did not change. Expenditures rose in all sectors, with business and higher education leading spending at ZAR 10.6 billion ($957 million) and ZAR 7.3 billion ($664 million), up […]
Chancellor George Osborne has allotted £5.9 billion ($9.2 billion), £1.1 billion per year, over the next parliamentary term to research infrastructure. Half of the £3 billion for supporting labs will be awarded based on competition. “Grand challenges” will receive £2.9 billion. Of that amount, £800 million will go toward projects including chemistry and nanotechnology research, […]
The Russian government’s goals for the sciences call for an update to the country’s scientific system. The goals are for R&D financing to make up 1.77% of GDP, Russian scientific publications to constitute at least 2.44% of the global total and the income of Russian scientists to be 200% that of the average in their […]
As of the end of October, the US FDA had conducted 97 inspections of the more than 600 pharmaceutical plants in India registered with the US. It found that at many facilities producing medicines for export to the US, samples of drugs failing to meet quality standards for purity were retested rather than discarded. Failed […]
Lansing, MI 12/8/14—Neogen, which develops and markets products for food and animal safety, has acquired the food-safety and veterinary-genomic assets of Beijing Anapure BioScientific, its Chinese distributor. Financial details were not disclosed. “China’s burgeoning middle class, with its rapidly growing demand for higher quality meat and dairy products, makes the country a substantial growth opportunity […]
In 2013, Turkey’s gross domestic expenditure on R&D (GERD) was TRY 14.8 billion ($7.8 billion), an increase of 13.4%. GERD as a percentage of GDP was 0.95%. Business enterprises, higher education and the public sector accounted for 48%, 42% and 10% of spending, respectively. Business, the government, higher education, other national sources and foreign funds […]
In 2013, business R&D spending in the UK was £18.4 billion ($28.8 billion), up 8%, to account for 1.1% of GDP. Civil and defense R&D expenditures were £16.7 billion and £1.7 billion, up 8% and 7%, respectively. Spending by foreign-owned business increased 11%, accounting for 54% of total R&D. Of the product groups selected by […]
Based on “The Nature Index,” which tracks research articles published in a group of journals chosen by a group of scientists, Israel contributed the most scientific research papers in 2013 of countries in West Asia. At more than 1,000, Israel’s article count (AC), the number of articles with at least one author from the country, […]
Germany’s federal and state governments will allot €25.3 billion ($31.6 billion) to special programs in research and higher education over the next six years. Most of it will be for universities. The federal government and states continue to provide about €20 billion to universities by 2020 to offset rising student numbers. The budgets of four […]
In 2013, national R&D spending grew 15.0% to CNY 1,184.7 billion ($193 billion). The proportion of R&D expenditures to GDP rose 0.1 percentage point to 2.1%. Spending on basic research, applied research and experimental development grew 11.3%, 9.2% and 16.0% to CNY 55.5 billion, CNY 126.9 billion and CNY 1,002.3 billion, respectively. Expenditures by “all […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
